The first branded generic alternative to Fostair, Luforbec 100/6 g pMDI, has been introduced in the UK by an Indian pharmaceutical company for the treatment of Asthma and COPD.
Lupin Healthcare (UK), a wholly-owned subsidiary of Lupin Limited (Lupin), announced that Luforbec (beclometasone/formoterol) 100/6 dose pressurised metered dose inhaler (pMDI) is now available to patients in the UK, following approval by the Medicines and Healthcare Products Regulatory Agency (UK-MHRA) earlier this year.
Luforbec is approved to treat adult asthma as well as the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD).
The United Kingdom National Health Service (UK NHS) spent more than 177 million on Fostair 100/6 pMDI in the year ending May 2021.
Lupin has been granted approval to produce Luforbec at its facilities in Pithampur, India, and Coral Springs, Florida, in the United States.
On a consolidated basis, the drugmaker's net profit increased 404.30 percent to Rs 548.16 crore in Q1 June 2021 (Q1 FY22) over Q1 June 2020, thanks to a 22.2 percent increase in net sales to Rs 4,237.39 crore (Q1 FY21).
Lupin's stock climbed 1.75 percent to Rs 940.90 on the BSE. Lupin is a global pharmaceutical business focused on innovation.